Items tagged with Medicines
Workshop: towards new treatments for TB (post)
The European Medicines Agency (EMA) is organising a workshop on the development of new medicines to treat tuberculosis (TB). The event will take place at EMA’s premises in London on 25 November 2016, from 9:00 to 16:00.
New capsule achieves long-term drug delivery (post)
Researchers at MIT and Brigham and Women’s Hospital have developed a new drug capsule that remains in the stomach for up to two weeks after being swallowed, gradually releasing its drug payload. This type of drug delivery could replace inconvenient regimens that require repeated doses, which would help to overcome one of the major obstacles to treating and potentially eliminating diseases such as malaria.
German government announces support for new TB treatments (post)
The government of Germany has announced its support for the development of new treatments to combat tuberculosis (TB). Germany’s Federal Ministry of Education and Research (BMBF) has committed EUR 10 million over five years to TB Alliance, facilitated by the KfW development bank. This grant is part of a slate of support intended to spur product development to fight neglected diseases.
U.S. government introduces new drug to help save lives of TB patients in Tajikistan (post)
Acting Deputy Chief of Mission of the United States to Tajikistan Lucy Jilka yesterday (January 31) joined the First Deputy Minister of Health and Social Protection of Population of Tajikistan Saida Umarzoda, national health leadership, physicians, TB doctors, and stakeholders to celebrate the introduction of bedaquiline to Tajikistan. This is the first new drug approved for the treatment of tuberculosis (TB) since the 1960s.
Structure of TB drug target determined (post)
Rutgers University scientists have determined the three-dimensional structure of the target of the first-line anti-tuberculosis drug rifampin. They have also discovered a new class of potential anti-tuberculosis drugs that kill rifampin-resistant and multi-drug-resistant tuberculosis bacteria.
EPFL non-profit iM4TB awarded $2.45m for anti-TB drug clinical trials (post)
21.04.17 - The Bill & Melinda Gates foundation has awarded EPFL-based non-profit iM4TB $2.45 million to take their innovative anti-tuberculosis drug PBTZ169 into clinical trials.
IGIB uses novel drug discovery approach to identify drug targets in TB bacteria (post)
In a completely different approach to drug discovery, a team led by Dr. Samir K. Brahmachari, a J.C Bose National Fellow, at Delhi’s CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB) has used a combination of approaches to predict potential drug targets in Mycobacterium tuberculosis, the TB-causing bacteria. The novel method not only helps in speeding up drug discovery by finding potential, non-toxic drug targets but will also cost far less by reducing the chances of failure. The results were published in the journal Scientific Reports.
Spero Therapeutics receives grant from National Institutes of Health to explore novel treatment combinations for TB (post)
CAMBRIDGE, Mass., May 4, 2017—Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, today announced that it has received a grant from the National Institutes of Health (NIH) to conduct additional preclinical studies of SPR720, the Company’s novel oral bacterial gyrase inhibitor, for the treatment of tuberculosis (TB). The non-dilutive grant of $564,718 is part of the NIH’s Small Business Innovation Research (SBIR) program (Grant Number: 1R44AI131749-01).
TB Treatment Trials Grid 2017 (post)
Michael Vjecha, MD compiled for the Tuberculosis Trials Consortium (TBTC) a table containing information about the planned, ongoing, and recently completed randomized TB drug clinical trials.
WHO prequalifies Mylan's India unit to supply TB drug API (post)
The WHO has prequalified Indian-based Mylan Laboratories Ltd to supply the tuberculosis drug ingredient protionamide.
Page 6 of 19 · Total posts: 0
←First 5 6 7 Last→